About eTheRNA
eTheRNA is a company based in Niel (Belgium) founded in 2013 by Kris Thielemans.. eTheRNA has raised $103.94 million across 8 funding rounds from investors including BNP Paribas Fortis, EQT and PMV. eTheRNA offers products and services including LNP Formulation Platform and mRNA Chemistry Platform. eTheRNA operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Niel, Belgium
- Founders Kris Thielemans
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Etherna Immunotherapies
-
Annual Revenue
$1.57 M (USD)430as on Dec 31, 2019
-
Net Profit
$-10.34 M (USD)18as on Dec 31, 2019
-
EBITDA
-
Total Equity Funding
$103.94 M (USD)
in 8 rounds
-
Latest Funding Round
$38.95 M (USD), Series B
Aug 23, 2022
-
Investors
BNP Paribas Fortis
& 13 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of eTheRNA
eTheRNA offers a comprehensive portfolio of products and services, including LNP Formulation Platform and mRNA Chemistry Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides tailored LNP formulations for targeted RNA delivery.
Enables sequence engineering for optimal mRNA stability and efficiency.
Unlock access to complete
Unlock access to complete
Funding Insights of eTheRNA
eTheRNA has successfully raised a total of $103.94M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $38.95 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series B — $38.9M
-
First Round
First Round
(14 Mar 2016)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2022 | Amount | Series B - eTheRNA | Valuation | Kenneth Chien , Novalis LifeSciences | |
| Mar, 2021 | Amount | Grant - eTheRNA | Valuation |
investors |
|
| Feb, 2021 | Amount | Grant - eTheRNA | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in eTheRNA
eTheRNA has secured backing from 14 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include BNP Paribas Fortis, EQT and PMV. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund.
|
Founded Year | Domain | Location | |
|
Venture capital firm
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by eTheRNA
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - eTheRNA
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Etherna Comparisons
Competitors of eTheRNA
eTheRNA operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Etherna
Frequently Asked Questions about eTheRNA
When was eTheRNA founded?
eTheRNA was founded in 2013 and raised its 1st funding round 3 years after it was founded.
Where is eTheRNA located?
eTheRNA is headquartered in Niel, Belgium. It is registered at Niel, Antwerp, Belgium.
Is eTheRNA a funded company?
eTheRNA is a funded company, having raised a total of $103.94M across 8 funding rounds to date. The company's 1st funding round was a Grant of $6.16M, raised on Mar 14, 2016.
What is the annual revenue of eTheRNA?
Annual revenue of eTheRNA is $1.57M as on Dec 31, 2019.
What does eTheRNA do?
eTheRNA was founded in 2013 and is based in Niel, Belgium, where mRNA-based immunotherapies for cancer and infectious diseases are developed. Proprietary TriMix technology is employed, featuring three mRNA moleculescaTLR4, CD40L, and CD70that enhance immune responses via the dendritic cell pathway. Focus is placed on applications for melanoma and breast cancer within the biotechnology sector.
Who are the top competitors of eTheRNA?
eTheRNA's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does eTheRNA offer?
eTheRNA offers LNP Formulation Platform and mRNA Chemistry Platform.
Who are eTheRNA's investors?
eTheRNA has 14 investors. Key investors include BNP Paribas Fortis, EQT, PMV, European Union, and Life Sciences Partners.